Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 2/20 | 0.45 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236255 | 0.86 | ESRRG (0.58) | DRD4DRD2DRD3PLGPLAU | |
| SCHEMBL6750680 | 0.84 | NOS3 (0.51) | DRD4DRD2DRD3PLGPLAU | |
| SCHEMBL4235481 | 0.84 | DRD2 (0.45) | DRD4DRD2DRD3ESRRGP2RX7 | |
| SCHEMBL4233332 | 0.79 | ESRRG (0.60) | PLGPLAUESRRGPLA2G4AACHE | |
| SCHEMBL1663349 | 0.78 | CD274 (0.49) | PLGPLAUESRRG | |
| SCHEMBL4813289 | 0.77 | PLG (0.55) | PLGPLAUPLA2G4AMCL1BCL2 | |
| SCHEMBL1749895 | 0.77 | PLA2G4A (0.59) | PLGPLAUPLA2G4AMCL1BCL2 | |
| SCHEMBL846081 | 0.76 | PLA2G4A (0.61) | PLGPLAUPLA2G4AMCL1BCL2 | |
| SCHEMBL12420731 | 0.75 | ACHE (0.53) | PLGPLAUPLA2G4AACHE | |
| SCHEMBL1664063 | 0.75 | PLG (0.51) | PLGPLAUESRRGPLA2G4AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | DRD4 423/4885DRD2 337/4885DRD3 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.